Literature DB >> 18519227

Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells.

Beata Pajak1, Barbara Gajkowska, Arkadiusz Orzechowski.   

Abstract

This review outlines the molecular events that accompany the anti-tumor action of parthenolide (PN). Parthenolide (PN) is naturally derived compound, isolated from plant Tanacetum parthenium. PN has been previously shown to withdraw cells from cell cycle or to promote cell differentiation, and finally to induce programmed cell death. Recent advances in molecular biology indicate that this sesquiterpene lactone might evoke the above-mentioned effects by indirect action on genes. PN was shown to inhibit NF-kappaB- and STATs-mediated antiapoptotic gene transcription. On one hand, the proapoptotic activity of PN includes stimulation of intrinsic apoptotic pathway with the higher level of intracellular ROS and modifications of Bcl-2 family proteins (conformational changes of Bak and Bax, Bid cleavage). On the other hand, PN amplifies the apoptotic signal through the sensitization of cancer cells to extrinsic apoptosis, induced by TNF-alpha. These effects are specific to tumor cells. Unique properties of PN make this agent a promising metabolic inhibitor to retard tumorigenesis and to suppress tumor growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519227     DOI: 10.2478/v10042-008-0019-2

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  25 in total

1.  The Feverfew plant-derived compound, parthenolide enhances platelet production and attenuates platelet activation through NF-κB inhibition.

Authors:  Julie Sahler; Jamie J Bernard; Sherry L Spinelli; Neil Blumberg; Richard P Phipps
Journal:  Thromb Res       Date:  2011-01-26       Impact factor: 3.944

Review 2.  Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities.

Authors:  Vivek Bhakta Mathema; Young-Sang Koh; Balkrishna Chand Thakuri; Mika Sillanpää
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

3.  Inhibitory effects of parthenolide on the activity of NF-κB in multiple myeloma via targeting TRAF6.

Authors:  Fan-Cong Kong; Jing-Qiong Zhang; Chen Zeng; Wen-Lan Chen; Wen-Xiang Ren; Guo-Xin Yan; Hong-Xiang Wang; Qiu-Bai Li; Zhi-Chao Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

4.  Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis.

Authors:  Alan T Yeo; John A Porco; Thomas D Gilmore
Journal:  Cancer Lett       Date:  2011-12-06       Impact factor: 8.679

5.  Parthenolide Induces Apoptosis in Committed Progenitor AML Cell line U937 via Reduction in Osteopontin.

Authors:  Mahdi Zahedpanah; Mojgan Shaiegan; Seyed Hamidollah Ghaffari; Mohsen Nikbakht; Mahin Nikugoftar; Saeed Mohammadi
Journal:  Rep Biochem Mol Biol       Date:  2016-04

Review 6.  Targeting mitochondria for cancer therapy.

Authors:  Simone Fulda; Lorenzo Galluzzi; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2010-05-14       Impact factor: 84.694

Review 7.  Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.

Authors:  Wamidh H Talib; Izzeddin Alsalahat; Safa Daoud; Reem Fawaz Abutayeh; Asma Ismail Mahmod
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

8.  KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells.

Authors:  Yong Xu; Fang Fang; Sumitra Miriyala; Peter A Crooks; Terry D Oberley; Luksana Chaiswing; Teresa Noel; Aaron K Holley; Yanming Zhao; Kelley K Kiningham; Daret K St Clair; William H St Clair
Journal:  Cancer Res       Date:  2013-05-14       Impact factor: 12.701

9.  In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player.

Authors:  Riccardo Di Fiore; Rosa Drago-Ferrante; Antonella D'Anneo; Giuseppa Augello; Daniela Carlisi; Anna De Blasio; Michela Giuliano; Giovanni Tesoriere; Renza Vento
Journal:  Cancer Biol Ther       Date:  2013-08-12       Impact factor: 4.742

10.  Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.

Authors:  Shanshan Pei; Mohammad Minhajuddin; Kevin P Callahan; Marlene Balys; John M Ashton; Sarah J Neering; Eleni D Lagadinou; Cheryl Corbett; Haobin Ye; Jane L Liesveld; Kristen M O'Dwyer; Zheng Li; Lei Shi; Patricia Greninger; Jeffrey Settleman; Cyril Benes; Fred K Hagen; Joshua Munger; Peter A Crooks; Michael W Becker; Craig T Jordan
Journal:  J Biol Chem       Date:  2013-10-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.